Dyslipidemia

Results of an analysis of more than 20 randomized trials indicates women are at a greater risk of MACE and all-cause mortality than men following PCI.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

Discussing a REDUCE-IT substudy presented at ACC.20/WCC examining the impact of various EPA levels on outcomes seen in REDUCE-IT.

Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.

Results of a TWILIGHT subanalysis suggest ticagrelor monotherapy might cause less bleeding without increasing events in patients with requiring complex PCI.

A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.

Results of a pooled analysis of trials from the ORION program offer further insight into the effects of inclisiran on LDL-C in patients with atherosclerotic cardiovascular disease.

Marc Bonaca, MD, discusses the results of a subgroup analysis examining the impact of concomitant clopidogrel use in VOYAGER-PAD study.

A new ACC 2020 study shows the modifiable levels of CVD risk are distinguishable to long-term event possibility.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.

Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

Marc Bonaca, MD, discusses the results of the VOYAGER-PAD trial in a special edition ACC House Call with HCPLive.

Data presented at ACC.20/WCC is shedding light on the impact of genotype-guided antiplatelet therapy in patients undergoing PCI for ACS or CAD.

Discussing how approval of bempedoic acid impacts the role of PCSK9 inhibitors for lowering LDL-C.

New findings show eligible men and minority group patients are less likely to receive a fill for the novel drug class.

An open-label extension of GLAGOV shows the monoclonal antibody plus statin therapy is not associated with any new safety concerns.

A special edition ACC House Call with Deepak Bhatt, MD, to discuss the results of a meta-analysis looking at ticagrelor and MALE from 2 clinical trials.

Executive Director of Interventional Cardiovascular Programs at Brigham and Women's discusses some research he took part in being presented at this year's conference.

The author of the first systematic evaluation of commissural alignment in TAVR shares his team's findings.

Data published in NEJM demonstrate the siRNA agent's ability to lower cholesterol in patients with multiple conditions.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Results of a meta-analysis of more than 2 dozen studies indicate DCB treatment may actually reduce mortality risk long-term.

New data from EPI Lifestyle Conference 2020 is shedding light on the impact of initiating estradiol therapy closer to the onset of menopause.

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.